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Unbalanced Th1/Th2 T-cell responses in the liver are a characteristic of hepatic inﬂammation and subsequent liver ﬁbrosis. The
recentlydiscoveredTh17cells,asubtypeofCD4+ T-helpercellsmainlyproducingIL-17andIL-22,haveinitiallybeenlinkedtohost
defense against infections and to autoimmunity. Their preferred diﬀerentiation upon TGFβ and IL-6, two cytokines abundantly
present in injured liver, makes a contribution of Th17 cells to hepatic inﬂammation very likely. Indeed, initial studies in humans
revealed activated Th17 cells and Th17-related cytokines in various liver diseases. However, functional experiments in mouse
models are not fully conclusive at present, and the pathogenic contribution of Th17 cells to liver inﬂammation might vary upon
the disease etiology, for example, between infectious and autoimmune disorders. Understanding the chemokines and chemokine
receptorspromotinghepaticTh17cellrecruitment(possiblyCCR6orCCR4)mightrevealnewtherapeutictargetsinterferingwith
Th17 migration or diﬀerentiation in liver disease.
1.Introduction
In homeostasis, the liver is not only exerting various
metabolic functions, but also serves as a central “immuno-
logical” organ. Blood coming from the gastrointestinal tract
via the portal vein is rich of potential antigens derived
from the gut-resident commensal microﬂora, ingested food,
or also pathogens under infectious conditions. Immune
cells that reside in or travel through the liver have the
potential to initiate either (a) innate and adaptive immune
responses in case of infections, for example, in response to
lipopolysaccharide (LPS) or bacterial superantigens or (b)
immunological tolerance to the vast majority of harmless
antigens during homeostasis [1]. Following liver injury,
induced, for example, by hepatitis viruses, alcohol abuse, or
nonalcoholic steatohepatitis, inﬂammation is a pathological
hallmark feature of chronic liver diseases. Sustained inﬂam-
mation then promotes liver ﬁbrosis and—as an end stage—
liver cirrhosis or hepatocellular carcinoma [2].
Inﬂammatory responses upon liver injury comprise
resident as well as inﬁltrating immune cells. It is well
known that innate immune cells are important triggers
of hepatic inﬂammation, because the liver is selectively
enriched in macrophages (Kupﬀer cells), natural killer (NK),
and natural killer T (NKT) cells [1]. In addition, the
inﬁltration of monocytes upon liver injury is an important
cellular mechanism to perpetuate chronic inﬂammation and
to activate proﬁbrogenic hepatic stellate cells (HSC) in mice
and men [3, 4]. However, during conditions of chronic liver
damage, adaptive immune cells are also crucially involved
in the pathogenesis of hepatic inﬂammation. For instance,
CD8+ and CD4+ T cells play important roles in hepato-
cellular damage, antiviral defenses (to hepatitis viruses), or
autoimmunity [5, 6]. This paper will present the concept of
diﬀerent CD4+ T-helper cell subsets and summarize their
proposed functions during liver diseases, with a focus on
the current knowledge about the role of Th17 cells and their
associated cytokines in liver inﬂammation in mice and men.
2. T-Helper CellSubsets
CD4+ T-helper cells are major players in adaptive immunity.
They provide help for antigen-presenting cells and CD8+
cytotoxic T lymphocytes to initiate and promote adaptive
immune responses. Activation of CD4+ T cells is critical for
the elimination of many invading pathogens, but inadver-
tently they can also become responsive to self antigens, thus2 Clinical and Developmental Immunology
leading to autoimmune diseases. In order to prevent this, the
diﬀerentiation and activation of CD4 T-helper cells has to be
tightly regulated.
Nowadays, CD4 T-helper cells are divided into four
major subsets, based on their expression proﬁle of tran-
scription factors and secreted cytokines: Th1, Th2, Th17,
and regulatory T cells (Treg) (Figure 1). The ﬁrst two
subsets, Th1 and Th2, were identiﬁed in the 1980s, when it
becameclearthatCD4+ Tcellscandevelopintoindependent
subsets [7]. Th1 cells are characterized by the secretion of
IFNγ, a proinﬂammatory cytokine which is necessary for the
activation of macrophages and involved in immunity against
intracellular pathogens [8, 9]. They have also been linked
to cell-mediated autoimmune diseases. Th2 cells produce
mainly IL-4, IL-5, and IL-13 and play an important role in
allergy as well as in the clearance of various extracellular
pathogens and parasites [8, 9].
Figure 1 summarizes key cytokines that drive the diﬀer-
entiation of T-helper cell populations, their main eﬀector
cytokines, and the characteristic transcription factors for the
diﬀerent subsets. The diﬀerentiation of Th1 cells is mainly
induced by IL-12 [9, 10] and can be further enhanced by
IFNγ. Th2 cells develop in the presence of IL-4 [10]. Th1
and Th2 negatively regulate each other through actions of
their speciﬁc cytokines: IL-12 represses the induction of Th2
cells, whereas IL-4 inhibits Th1 cell development. On the
transcriptional level, Th1 polarizing cytokines induce the
transcription factors T-bet and STAT4, whereas Th2 cells
require the action of GATA3 and STAT6 [11].
Regulatory T cells (Treg) are a unique subset of CD4+ T-
helper cells that control eﬀector T-cell responses to prevent
autoimmune reactions. Activated Treg produce the anti-
inﬂammatory cytokines IL-10 and TGFβ, thus suppressing
the development of functional immune reactions [12]. The
diﬀerentiation of Treg is induced by TGFβ [13, 14]b u t
inhibited in the presence of proinﬂammatory cytokines. Treg
cells are characterized by the expression of the transcription
factors Foxp3 and STAT5 and the expression of CD25 on
their surface [15].
Th17 cells are a more recently discovered subset of
CD4+ T-helper cells characterized by the production of their
signature cytokine IL-17. They represent another subtype of
proinﬂammatory T-helper cells that diﬀers from Th1 and
Th2 cells in development and function. Diﬀerentiation of
Th17cellsneedsthecombinedactionsofTGFβ,IL-6,andIL-
21 in mice [16–18], whereas IL-6 and IL-21 can be replaced
b yI L - 2 3o rI L - 1 β in humans. These cytokines induce the
expression of the orphan nuclear receptor RORγt( m i c e )
or RORc (human) [19, 20]. RORγt (or RORc) is necessary
and suﬃcient for the development of Th17 cells [21], but
the transcription factors RORα and STAT3 are also activated
[22, 23]. Development of Th17 cells is suppressed by IFNγ
and IL-4 that promote Th1 or Th2 cells, respectively [24].
TGFβ alone, in absence of other proinﬂammatory cytokines
like IL-6, induces FoxP3+ regulatory T cells instead of Th17
cells, which shows the close relationship between Th17 and
Treg. Once Th17 cells have developed, IL-23 is needed for
stabilization and further expansion of these cells in mice
[25,26].ForhumanTh17cells,alsoIL-1β andIL-6canactto
enhance development and expansion of these cells. Activated
Th17 cells secrete IL-17A, IL-17F, IL-21, IL-22, and TNFα,
which then promote tissue inﬂammation by induction
of other proinﬂammatory mediators and recruitment of
leukocytes, mainly neutrophils, to the site of inﬂammation
[27, 28]. IL-17 can induce the expression of neutrophil-
attracting chemokines, like CXCL1, CXCL2, or CXCL8 in
various cell types, among them a variety of epithelial and
endothelial cell types, but IL-17 itself can also act to mobilize
and activate neutrophils [29, 30].
For nonimmune cells of the liver, there is not much
known about the eﬀects of IL-17 so far. It has been shown
that stimulation with IL-17 induces the expression of several
inﬂammation-associated genes, including chemokines and
C-reactive protein, in primary hepatocytes [31, 32]. These
eﬀects can be enhanced by adding TNFα or IL-1, and this
strongly suggests a role in sustaining liver inﬂammatory
processes for Th17 cells. Human biliary epithelial cells have
been described to express IL-6, IL-1β, IL-23p19, and several
chemokines (CXCL1, CXCL8, CCL20, and others) upon
stimulation with IL-17 [33]. As all these cytokines and
chemokines are associated with Th17 cells, biliary epithelial
cells seem to be able to enhance and sustain Th17-type
responses. Interestingly, IL-23p40, the shared subunit of IL-
23 and IL-12 that would also favour Th1-type responses, is
not upregulated.
Th17 cells have been shown to be involved in the
clearance of extracellular bacteria and fungi [34, 35]. They
are abundant in the intestinal lamina propria where they are
induced by commensal bacteria and function as a barrier
against invading pathogens [36], but they have also been
linked to several autoimmune diseases. This has ﬁrst been
shown in mice lacking the IL-23 subunit p19 [37], thus not
being able to mount eﬀective Th17 responses because IL-
23 is needed for stabilization. These animals show normal
numbers of Th1 cells but were protected from development
of experimental autoimmune encephalomyelitis, the mouse
model for multiple sclerosis [37]. Similar observations have
been made in IL-17-deﬁcient mice that show less severe
autoimmune reactions than wild-type mice [38]. Since their
discovery, IL-17-producing T cells have been found to
be present at the site of inﬂammation in several human
inﬂammatory and autoimmune diseases like inﬂammatory
bowel’s disease, rheumatoid arthritis, multiple sclerosis, and
others [39, 40]. Taken together, these ﬁndings suggest that
Th17 responses play an important part in inﬂammatory
tissue injury and autoimmunity in humans.
3. Th17 Cellsin ExperimentalMurineLiver
Injury Models
3.1. T-Cell-Mediated Hepatitis. A widely used murine model
for T-cell-mediated hepatitis is Concanavalin A- (ConA-)
induced hepatitis [41]. Intravenous administration of ConA
results in rapid liver inﬂammation and necrosis, and many
features of ConA injury are believed to resemble human
autoimmune liver disorders. Establishment of the disease
involves a variety of cell types [42] and is dependent onClinical and Developmental Immunology 3
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Figure 1: Diﬀerentiation of CD4+ T-cell subsets (in mice). Upon activation, na¨ ıve CD4+ Tc e l l sc a nd i ﬀerentiate into diﬀerent subsets
depending on the surrounding cytokine milieu. The diﬀerent subpopulations show distinct expression patterns of transcription factors
and can be characterized by secretion of signature cytokines that are unique for each subset. Each subset takes part in diﬀerent kinds of
immune responses against various pathogens or in mediating autoimmunity.
activation of CD4+ T cells, as depletion of these cells
ameliorates hepatic injury [43]. CD4 T-cell cytokines IFNγ
and IL-4 have been shown to play a central role in ConA-
induced hepatitis [44, 45], whereas the role of IL-17 is
less clear, as recent studies have shown controversial eﬀects
since IL-17-deﬁcient mice were reported to develop the
same level of liver injury as wild-type mice, suggesting
that IL-17 plays no role in T-cell-mediated hepatitis [46];
in contrast, two other groups [43, 47] showed that IL-17-
deﬁcient mice develop reduced liver injury compared to wild
type mice. Although these diﬀerences were not as prominent
as in IFNγ- or IL-4-deﬁcient mice, where induction of liver
injury is almost completely suppressed [44, 45], they were
still signiﬁcant. These ﬁndings suggest that IFNγ and IL-
4 are essential for T-cell-mediated hepatitis, whereas IL-
17 is less important. This could be due to the fact that
IFNγ and IL-4 cause many directly damaging eﬀects on the
liver, including induction of proinﬂammatory cytokines and
causing hepatocyte apoptosis [45]. IL-17 also activates other
cells in the liver to produce proinﬂammatory cytokines, but
i th a sb e e nr e p o r t e dt oh a v eb e n e ﬁ c i a le ﬀects on hepatocyte
apoptosis[47,48].Theseantagonizingeﬀectsmightlimitthe
importance of IL-17 for T-cell-mediated hepatitis.
3.2. Parasitic and Bacterial Liver Infections. C57Bl/6 mice
infected with the helminth Schistosoma mansoni develop
mild ﬁbrosing inﬂammation against parasite eggs in the
liver leading to the formation of small granulomas around
these eggs [49, 50]. This immunopathology can be markedly
aggravated by immunization with soluble egg antigens in
complete Freud’s adjuvant (CFA) and was originally believed
to be Th1 mediated because the disease correlated with
high levels of IFNγ [51]. Several more recent studies
now revealed that the development of these granulomas
is primarily dependent on Th17 responses [52–54]. Mice
lacking the IL-12p35 subunit, thus able to make IL-23 but
not IL-12, are highly susceptible to Schistosoma infections
with severe immunopathology, whereas mice lacking IL-
12p40, therefore incapable of making IL-12 or IL-23, are
resistant to this pathology. Consistently, in vivo treatment
with neutralizing anti-IL-17 antibodies signiﬁcantly reduces
formationofhepaticgranulomas[54].InIL-23p19knockout
mice, immunopathology after Schistosoma infection is not
erased but signiﬁcantly reduced, which goes along with a
decrease in IL-17 and IFNγ production in granulomas and
impaired recruitment of immune cells to the lesions [53].
Taken together, these ﬁndings suggest that Th17 responses
are essential for the establishment of schistosome egg-
induced immunopathology with IL-23 playing a key role.
Furthermore, a study in T-bet knockout mice, which are
unable to mount Th1 responses, revealed that these mice
show more severe immunopathology with higher levels of
IL-17 and IL-23p19, indicating that this immunopathology
is mediated only by Th17 and that Th1 responses might as4 Clinical and Developmental Immunology
well protect against exacerbation of immunopathology by
negatively regulating Th17 responses [52].
Generally, Schistosoma infection causes only mild
immunopathology due to the induction of Th2 cells that
fulﬁl protective functions. Rutitzky et al. used the CFA
immunization model eliciting a strong Th1 response, which
caused severe immunopathology. However, the recent ﬁnd-
ing that the aggravation of disease might be rather due to
Th17 cells and that Th1 cells are more likely protective in
this case suggests that this might not only be true in this
experimental setting but also for other natural helminth
infections.
IL-17 has also been linked to innate immunity after
bacterial infection of the liver, where it seems to fulﬁl a
protectiveroleratherthanbeingresponsiblefordevelopment
of immunopathology. It has been reported that not only
classical TCRαβ T cells are able to produce IL-17 but also
some TCRγδ T cells that are associated with innate immune
reactions [55, 56]. In a model of Listeria monocytogenes
infection in the liver, IL-17 produced by γδ T cells is critical
for protective immunity in early stages of the infection
[57]. IL-17 expression in the liver increases shortly after
infection, and mice lacking IL-17 develop much more severe
immunopathologythanwild-typemice.Themainsourcefor
IL-17inthisearlystageisγδ Tcells,andtheauthorsconclude
that IL-17 producing γδ T cells take part in protective
immunity before adaptive Th17 cells appear.
As described above, IL-17 can have opposing eﬀects on
diﬀerent infection models. One possible explanation might
be that the time point of IL-17 appearance is diﬀerent
between the two models, which can lead to diﬀerent
functions. In Listeria infection, IL-17 is produced by innate
immune cells at a very early stage of infection and amelio-
rates the disease, whereas in infection with Schistosoma, mice
develop an adaptive immune response where Th17 cells fulﬁl
thefunctionsleadingtoimmunopathology.Thismightmean
that IL-17 can take part in protective processes if released in
an early innate environment, but it exerts more aggravating
actions in the context of adaptive immune reactions.
3.3. Cholestatic and Autoimmune Injury. Primary biliary
cirrhosis (PBC) is an autoimmune liver disease in humans
characterized by the formation of autoreactive antibodies
as well as the damage and loss of small bile duct cells
[58, 59]. IL-2Rα knockout mice have been identiﬁed as
an animal model for human PBC as they spontaneously
produceautoantibodiesanddevelopbiliaryducturaldamage
resembling that of PBC patients [60]. This overall increased
proinﬂammatory immune status compared to wild-type
mice might very well be due to a loss of functional regulatory
T cells. Treg cells need IL-2Rα (or CD25) to fulﬁl their anti-
inﬂammatory capacity and prevent autoimmunity. Thus IL-
2Rα KO mice develop spontaneous autoimmune reactions
like the ones mentioned above. This provides the opportu-
nity to study underlying mechanisms of immunopathology
that would otherwise be obscured by interfering interfering
mechanisms exerted by Treg cells.
IL-2Rα KO mice show altogether elevated levels of Th17
cells, probably due to the missing repressive eﬀect of IL-2
on the induction of Th17 cells accompanied by higher levels
of IL-17 in the serum [61]. Furthermore, IL-2Rα KO mice
show a higher frequency of Th17 cells in the liver compared
to wild-type mice [62]. Liver Th17 cells from IL-2Rα KO
mice also produce greater amounts of IL-17 than Th17 cells
isolated from wild-type mice. The same group also found
that in livers of IL-2Rα KO mice the ratio of Th17 cells to
Th1cellswasmuchhigherthaninthespleen.Wild-typemice
showed the same tendency, although much less prominent,
suggesting a preference of Th17 over Th1 responses in the
liver. This hypothesis is further supported by the fact that
nonparenchymal cells from the liver of wild-type mice can
induce splenic CD4+ T cells to produce IL-17. However, the
mechanisms of Th17 induction in the liver remain unclear.
Also, further studies are needed to investigate whether PBC
is really caused by Th17 cells and elevation of IL-17, for
instance, in IL-2Rα KO mice that are also unable to produce
IL-17.
3.4. Toxic Liver Injury. Halothane-induced liver injury is an
animal model for drug-induced liver injury. Mice injected
intraperitoneally (i.p.) with halothane show elevated levels
of serum transaminases and inﬁltration of immune cells
into the liver, which causes mild liver injury [63]. In
these mice, plasma levels of IL-17 are increased, and i.p.
administration of a neutralizing anti-mouse IL-17 antibody
decreases serum AST and ALT levels. Expression levels of
proinﬂammatory cytokines like TNFα in the liver were also
reduced. Accordingly, administration of recombinant IL-17
elevated plasma transaminases [64], thus aggravating liver
injury. This strongly indicates that IL-17 and Th17 cells are
involved in halothane-induced liver injury.
4.Th17 CellsinHumanLiverDiseases
IL-17producingThelpercellshavereceivedalotofattention
since their discovery as a committed lineage of T helper
cells in 2005. Since then, they have led to a reevaluation
of many disease phenotypes regarding their underlying
immunopathophysiology. In human liver disease, there is
accumulating evidence for the involvement of Th17 cells in
a variety of inﬂammatory processes in the liver, including all
major disease entities such as alcohol induced liver injury,
non-alcoholic steatohepatitis (NASH), viral hepatitis, hep-
atocellular carcinoma (HCC) and primary biliary cirrhosis
(PBC)aswellasgraftrejectionafterlivertransplantationand
autoimmune hepatitis. To give a short, coherent overview
regarding the potential involvement of Th17 cells, some of
the most recent ﬁndings of each disease phenotype shall be
reviewed in brief individually.
4.1. Alcohol-Induced Liver Disease (ALD). Alcohol induced
liver disease is accompanied by a severe secondary inﬂam-
matory reaction following the initial phase induced by toxic
metabolites derived from the degradation of ethanol by
cytochrome CYP2E1 [65]. The severity of inﬂammation is
directly linked to the amount of subsequent liver damage
[66]. Degradation of ethanol via cytochrome P450 2E1Clinical and Developmental Immunology 5
furthermore leads to the induction of PPARα signalling as
well as formation of reactive oxygen species (ROS) and acti-
vationofTNFαproductionandTRAIL-mediatedhepatocyte
apoptosis [67]. Regarding the inﬁltration of leukocytes into
inﬂamed liver tissue, T cells have been described as a major
partoftheinﬂammatoryresponsefollowingalcohol-induced
liver injury, showing high activity for example by secreting
a variety of inﬂammatory cytokines such as IL-1β,I L - 6 ,
and TNFα in vitro after isolation [68]. Furthermore, this
inﬁltration is accompanied by large amounts of neutrophils
that also invade the liver tissue and are commonly found
in alcohol-induced apoptotic lesions in close association to
dying hepatocytes [69, 70] .Ar e c e n ts t u d yb yL e m m e r s
et al. could show a close correlation between neutrophil
recruitment and the presence of IL-17 producing T-helper
cells within the inﬂammatory liver inﬁltrates in patients after
alcohol-induced liver intoxication [71]. They demonstrated
that ALD patients not only showed a signiﬁcant increase in
both IL-17 plasma titers and frequency of IL-17+ T cells,
but also displayed a correlation between liver inﬁltration of
neutrophils and Th17 cells. Furthermore, they could show
that Th17 cells produced IL-8 as well as GROα and that
these factors were both necessary and suﬃcient to induce
recruitment of neutrophils [71].
4.2. Nonalcoholic Steatohepatitis (NASH). Obesity accompa-
nied by metabolic syndrome and steatohepatitis is one of
the most common causes for chronic liver inﬂammation
leading to progressive tissue injury and liver ﬁbrosis. Albeit
the immunopathology of NASH is poorly understood to
date, various studies suggest an immediate link between
inﬂammatory response and subsequent liver damage. In
general, the induction of misdirected lipid oxygenation by
by P450 cytochromes such as CYP2E1 and CYP4A can
lead to the formation of free radicals and the formation of
reactive oxygen species (ROS), which can act as intrinsic
danger signals and triggers of inﬂammatory responses such
as macrophage activation and secretion of cytokines such as
TGFβ,T N F α, and IL-6, leading, for example, to activation of
TRAIL signaling and hepatocyte apoptosis [72, 73]. Hence,
the balance between oxidants and antioxidants critically
inﬂuences the severity of liver injury, acting as key players
in the induction of NASH [73, 74]. The involvement of
the adaptive immune response has currently been described
in the context of the classical Th1/Th2 paradigm [75], but
there is also evidence emerging for a potential involvement
of Th17-mediated T-cell responses. For instance, fatty liver-
associated inﬂammation is commonly accompanied by an
inﬁltration of perivenular and periportal inﬁltration of
both neutrophils and lymphocytes, suggesting an enhanced
recruitment via their two major receptors CXCR1 or CXCR2
[74, 76]. However, the exact functional role of the neu-
trophils as well as the recruiting mechanisms still have
to be further elucidated, although several studies propose
an active involvement rather than being only bystander
cells that are recruited due to inﬂammation [70, 74, 75].
Takentogether,thecloselinkbetweenneutrophilinﬁltration,
IL-6 signalling, and Th17 responses [27, 28] and their
presence in NASH suggests a functional correlation between
fatty liver-induced inﬂammation and a Th17 immune
response.
4.3. Viral Hepatitis. In both chronic Hepatitis B (HBV) and
Hepatitis C Virus (HCV) infections, recent reports indicate a
close correlation between virus-induced liver inﬂammation,
inﬁltration and activation of Th17 cells and the amount
of liver damage caused by the antiviral immune response.
For instance, a close correlation between liver inﬁltrating
as well as circulating Th17 cells and the amount of liver
damage has been shown in chronically infected Hepatitis B
patients. A shift from Th1 to Th17 seems to be potentially
disadvantageous for the patient in terms of antiviral defense
and liver disease progression, since stronger Th17 responses
are associated with higher viral plasma load, increased levels
of serum transaminases, and enhanced activation of blood
monocytes as well as liver macrophages. Antigen-speciﬁc
responses of virus-speciﬁc Th17 cells have been described for
both HBV and HCV, leading to similar pathophysiological
changes in both infections [34, 71, 77]. For HBV, HBcAg
especially has been shown to be one of the key Th17-
inducing antigens, leading to an IL-17R-induced activation
of macrophages and monocytes followed by upregulation
of CD86, B7H1, B7DC, and CD83 and also cytokines such
as IL-1β,I L - 6 ,T N F α, IL-23p19 and IL-12p35 [78]. Finally,
it has been reported that antiviral therapy with pegylated
interferon and ribavirin in HCV-infected patients leads to
a reduction of both Th1 and Th17 responses, ameliorating
HCV-mediated liver inﬂammation [79].
4.4. Hepatocellular Carcinoma (HCC). In HCC formation,
regulating and suppressing antitumoral immune responses
is one of the major hallmarks of progressive liver tumor
development. Several studies also suggest an involvement
of Th17 cells in enhanced tumor formation and survival
as well as a negative correlation between tumor-associated
Th17 responses and patient survival. As indicated by a study
by Hou et al., Th17 cells in general can perform anti-
apoptotic functions, which can generally be beneﬁcial for
the survival of HCC tumor tissue [80]. Tumor-inﬁltrating
Th17 cells express high levels of CCR4 and CCR6 and
therefore respond to tumor-derived CCL20 signals [81].
Furthermore, it has been shown that CD68+ HCC-stroma-
associated macrophages are able to induce Th17 T-cell
responses rather than acting as myeloid-derived suppres-
sor cells (MDSC), therefore potentially directing tumor-
associated T-cell responses into a Th17-type direction [82].
The functional role of Th17 cells in supporting tumor
formation or survival is only poorly understood up to date
and remains somewhat controversial, since in viral hepatitis
aswellasALD-Th17cellshavebeendescribedtobeproapop-
totic. It has been suggested that IL-17 and IL-23 can act as
angiogenic factors, therefore promoting tumor survival [81,
83–85]. One explanation for these opposed ﬁndings could be
thefundamentallydiﬀerentdiseaseentityofaliver-damaging
agent such as a pathogen or a toxin on the one hand and a
relatively immunologically inert or even immunosuppressive
environment created by growing tumor tissue on the other
hand. On the one hand, danger sensing and inﬂammation6 Clinical and Developmental Immunology
could lead to a feed-forward loop where Th17 cells would
aggravate the subsequent inﬂammation; on the other hand,
proangiogenic functions would promote survival of tumor
tissue due to enhanced oxygenation, therefore preventing
tissue necrosis and activation of immune cells by the release
of danger signals.
4.5. Primary Biliary Cirrhosis (PBC). Primary biliary cir-
rhosis (PBC) is directly linked to a large inﬂammatory
response due to the presence of highly immunogenic danger
signals such as malsecreted bile acids, which accumulate
in liver parenchyma owing to obstruction of either small
or large bile ducts. Several studies have shown a close
correlation between formation of PBC and Th17 immune
responses in humans, demonstrating a skewed balance from
a Treg response towards Th17 in liver inﬁltrating as well as
circulating T-helper cell subtypes [86]. Furthermore, it has
also been reported that biliary epithelial cells can directly
respond to IL-17, express IL-17R, and upon engagement,
start producing acute inﬂammatory signals such as IL-6,
IL-1β, and IL-23. Finally, PBC has been described to be
accompanied by a direct inﬁltration of IL-17+ cells into
damaged bile ducts [33, 62].
4.6. Liver Transplantation/Graft Rejection. In liver transplan-
tation and liver graft rejection, only limited evidence exists
up to now that suggests an involvement of Th17 cells.
However, a study presented by Fabrega et al. describes a
possible correlation between acute liver rejection and Th17
induction, showing an overall increase in serum IL-17/IL-23
after transplantation compared to healthy controls in general
as well as an even more pronounced IL-17/IL-23 response
upon acute graft rejection [87].
4.7. Autoimmune Hepatitis. The exact immunopathology of
autoimmune hepatitis is still unknown, but the involvement
of liver-speciﬁc T-cell responses has been suggested for
example against liver-derived antigens such as CYP2D6
antigen, a hepatic P450 cytochrome that can act as a
class II restricted antigen, leading to the loss of Treg cell
function and shifting to an autoimmune T-cell response
[88]. Although the exact contribution of Th17 cells to
autoimmune hepatitis is unclear, in acute liver inﬂammation
high levels of plasma IL-17 could be detected in patients
suﬀering from autoimmune hepatitis [89].
Taken together, Th17 cells appear to be involved in the
pathogenesisofhumanliverdisease,likelymediatingdistinct
immunological functions. On the one hand, Th17 cells are
actively engaged in the induction and orchestration of innate
immune responses, neutrophil recruitment, and neutrophil
activationascommonlyseeninALD,NASH,andPBC.These
aberrant inﬂammatory responses are likely to be critical
factors for liver injury and damage progression. On the
other hand, Th17 cells can also induce anti-inﬂammatory
responses and drive tissue growth and angiogenesis as seen
in HCC. After viral infection with HBV or HCV, it remains
to be elucidated whether Th17 cells promote liver damage
and are directly involved in enhanced virus survival or if
they are simply less capable compared to Th1 T-helper cells
in the induction of antiviral responses and therefore are
not as competent in limiting disease progression and viral
spreading and persistence.
5. Interference with Th17 Cell Migration as
PotentialTherapeutic Target
Lymphocyte migration and chemokine-mediated traﬃcking
has been studied extensively over the last two decades.
The rationale for a thorough understanding of lymphocyte
migration in various inﬂammatory conditions is that this
would possibly allow interfering with these chemokine
pathways as novel therapeutic approaches. Although no
chemokine-directed drug has been introduced for the
treatment of liver diseases yet, much has been learned
about leukocyte traﬃcking in various experimental settings,
leading to the identiﬁcation of key receptors and their related
ligands for migration of lymphocyte subpopulations such as
B cells, cytotoxic T cells and T-helper cells in homeostasis
and inﬂammation. For instance, CCR7 and CXCR5 have
been described as the most important chemokine receptors
mediating lymphocyte traﬃc towards and within secondary
lymphatic organs in constitutive migration and turnover,
whereas CCR1, CCR5, CXCR3, CCR3, and CCR4 have
clearly been linked to recruitment of T lymphocytes into
inﬂamed peripheral tissues [90].
In particular, the diﬀerential migration of T helper cell
subsets critically inﬂuences the outcome of the subsequent
immune response following lymphocyte inﬁltration. For
Th1- as well as Th2-type immune responses, these rela-
tionships have been studied in great detail and have been
reviewed elsewhere [90–93]. In brief, CCR5 and CXCR3
have been described to be involved in migration of Th1 T-
helper cells in various inﬂammation models, responding to
chemokines such as CCL3 (MIP-1α), CCL4 (MIP-1β), and
CCL5 (RANTES) as well as CXCL9 (MIG), CXCL10 (IP-
10), and CXCL11 (ITAC) [91, 94–97]. In contrast, CCR3
and CCR4 have been described as the main receptors
involved in traﬃcking of Th2 T-helper cells, responding
to signals such as CCL11 (Eotaxin-1), CCL13 (MCP-4),
and CCL26 (Eotaxin-3) as well as CCL17 (TARC) and
CCL22 (MDC) [91, 95, 98, 99]. Although this has not been
fully conﬁrmed for each receptor or ligand in liver disease,
experimental evidence supports the assumption that most of
these pathways also apply to settings of liver inﬂammation
(Figure 2)[ 100].
For regulatory T cells the picture is a lot less clear, since
thereseemstobe atleastapartial functionaloverlap between
signals that mediate immunity or tolerance. Migration of
Treg has been associated with CCR4- as well as CCR5-,
CCR6-, and CCR8-mediated signaling and their cognate
chemokines,butthereseemstobeahighdegreeofvariability
depending on the type of inﬂammation and the target tissue
in terms of the homing properties of these cells [101–104].
The exact function of Treg in hepatic disease and their
migration into the liver is still a matter of debate; however,
CCR4 and CXCR3 appear to be involved in Treg recruitment

























































Figure 2: T-cell-mediated inﬂammation of the liver. Four diﬀerent types of T-helper cell responses have been described to inﬂuence various
inﬂammatory processes in the liver. Th1 responses lead to classical activation (M1) of liver-resident macrophages such as Kupﬀe rc e ll sa sw e ll
as recruitment of monocytes from the bloodstream, promoting a proinﬂammatory environment by secretion of IFNγ,T N F α, and IL-12.
Th1 inﬁltration is mediated mainly by engagement of chemokine receptors CXCR3 and CCR5. Th2-type responses are thought to lead to an
alternative activation of macrophages (M2) via IL-4 and IL-13, leading to a proﬁbrotic response by activation of hepatic stellate cells (HSC)
and inducing their diﬀerentiation into myoﬁbroblasts. Th2-type responses are linked mainly to CCR3- and CCR4- mediated chemokine
signalling as well as potentially CCR8 under certain conditions. Th17 cell responses in the liver have only recently been described to be
involved in various inﬂammatory processes induced, for example, by alcohol-induced liver disease, HCC, or HBV/HCV-induced hepatitis.
Th17 cells lead to activation of macrophages and recruitment of neutrophils, inducing an innate response by secretion of cytokines such
as IL-1β, IL-6, and TNFα but also regulatory factors such as TGFβ. Recruitment of Th17 cells may be associated with CCR6- and possibly
also CCR4-mediated signalling. T regulatory cells (Treg) have been described to be mainly immunosuppressive, secreting anti-inﬂammatory
cytokines such as IL-10 and TGFβ as well as consuming IL-2, which is a key factor for immunogenic activation of T cells. Therefore, Treg
inhibit and suppress T-cell activation and eﬀector functions as well as preventing activation of innate immune cells. A broad variety of
chemokine receptors have been linked to Treg migration, for example, CCR1 and CCR4 but also CCR5 as well as CCR6, suggesting a
functional overlap for these receptors in diﬀerent T-helper cell responses.
Understanding the migratory fate of Th17 cells has been
of particular interest over the last couple of years, since
understandingthedistributionandrecruitmentofthesecells
in homeostasis and inﬂammation might also shed some light
on their immunological function. Because recent reports
suggest a coevolution of Treg and Th17 cells [106], it is also
suggestive that there is also at least some redundancy in the
recruitment of these two T-helper cell subtypes. Indeed, it
has become clear that receptors such as CCR6 as well as
CCR4 seem to be the main chemokine receptors driving
inﬁltration of Th17 cells in homeostasis and inﬂammation.
In homeostatic conditions, CCR6/CCL20 (MIP3α)a p p e a r s
to be the main regulator promoting Th17 cell migration into
the Peyer’s patches of the gut, where the balance between
immigration of Th17 and Treg cells critically inﬂuences the
development of either immunity or tolerance [107]. The
recruitment of Th17 cells into the liver, either in homeostasis
or inﬂammation, has not been studied in great detail yet8 Clinical and Developmental Immunology
due to the fact that interest in Th17 cells in liver disease has
emerged only over the past few years.
Various disease models such as experimental autoim-
mune encephalomyelitis (EAE), systemic lupus erythemato-
sus (SLE), or nephrotoxic glomerulonephritis (NTN) have
been linked to inﬁltration of Th17 cells, most of them
reporting CCR6 as a key factor for Th17 inﬁltration into the
target tissues as well as a potential role for CCR4-directed
migration [104, 108–112]. Furthermore, priming of Th17
cells has also been described to be critically dependent on
CCR7-directed migration of antigen-presenting dendritic
cells (DC) and their subsequent production of IL-23p19 in a
model of EAE [112]. Functionally, Th17 cells are thought to
mainly initiate an innate immune response especially by the
recruitment of neutrophils via CXCL8, CXCL2, and CXCL5
directed signalling (targeting CXCR1 and CXCR2), as it has
beendescribed forexampleinmodels ofrenalcellcarcinoma
[113], uveitis [114], or renal inﬂammation [115]. There is
also some evidence for a potential signal ampliﬁcation loop
between neutrophils and Th17 cells, since activated neu-
trophils also have been reported to produce large amounts
of CCL20 under some conditions and therefore potentially
also are able to induce or maintain a Th17-type response
[116]. In humans, the migratory fate of Th17 cells seems to
be less clear up to now, since a variety of receptors associated
with either Th1, Th2 or even Treg have been described to be
expressed also on Th17 cells such as CCR2, CXCR3, CCR5,
CXCR6 but also CCR4 as well as CCR6, CCR7 and CXCR5
[117]. Extensive research activities are currently underway to
unravelthemigratorypathwaysofTh17cellsinexperimental
liver injury and in human liver diseases.
The approach to therapeutically interfere with migratory
pathways of Th17 or other immune cell subsets via blocking
of chemokine—chemokine receptor interactions is generally
appealing,asthiscouldpossiblybeahighlyselectivestrategy.
However, other components of the immune reaction could
also serve as therapeutic targets, for example, eﬀector or
Th17-diﬀerentiation cytokines. For instance, neutralizing
antibodies against IL-17 or IL-23 might be useful in liver
diseases, while neutralization of IL-6 could be potentially
harmful due to its overall protective eﬀects in chronic
liver injury [118]. Also, a local rediﬀerentiation or de-
novo diﬀerentiation of T-helper cell subsets in the inﬂamed
liver seems possible given the diﬀerentiation protocols used
for in vitro generation of Th17 cells, but would certainly
require a better understanding of the appropriate cytokine
cocktail and a highly speciﬁc delivery system to the injured
liver.
6. Conclusions and Outlook
Perpetuated inﬂammation and subsequent hepatic ﬁbrosis
are common characteristics of chronic liver diseases in
humans and have long been thought to be primarily
associated with unbalanced Th1/Th2 responses in the liver.
H o w e v e r ,t h i sc u r r e n tv i e wm a yh a v et ob er e v i s e di ns o m e
aspects since the recently discovered Th17 cells may also play
an active role in shaping the local inﬂammatory response
in the liver. Their preferred diﬀerentiation upon TGFβ and
IL-6 stimulation, two cytokines known to be abundantly
present in the injured liver, makes a contribution of Th17
cells to hepatic inﬂammation very likely. The major hallmark
of Th17 cells is the production of cytokines such as IL-
17 and IL-22 as well as the recruitment and activation of
neutrophils, and they have been described to play important
rolesnotonlyinhostdefenceagainstmicrobialinfectionsbut
also in tissue inﬂammation during autoimmunity regarding
liver disease; initial studies in humans and mice indeed also
revealed activated Th17 cells and Th17-related cytokines in
various liver diseases. However, neither the studies linked to
human liver diseases such as HBV/HCV infections, NASH,
HCC, or toxic liver damage nor functional experiments
in diﬀerent murine models are fully conclusive at present.
The exact pathogenic contribution of Th17 cells to liver
inﬂammation might very well vary upon the underlying
disease, for example, between infectious and autoimmune
disorders. Therefore, it will be of outstanding importance to
understand the function of Th17 cells in acute and chronic
liverinﬂammationandalsohepaticﬁbrogenesisaswellasthe
chemokines/chemokine receptors promoting hepatic Th17
cell recruitment in order to gauge whether interference with
Th17 migration or diﬀerentiation might represent a novel
target for the treatment of liver disease.
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